To review the research progress of C terminal propeptide of collagen type II (CTX-II), a osteoarthritis (OA) biomarker.
Domestic and international literature about CTX-II was reviewed extensively and summarized.
CTX-II is investigated broadly and has the best performance of all currently available biomarkers. CTX-II is a truly useful biomarker for early diagnosis, prognosis, and measurement of treatment response in OA.
Single CTX-II may be not sufficient for early diagnosis and prognosis of OA, so a combination of CTX-II and other biomarkers or diagnosis methods is needed.